Cencora (NYSE:COR – Get Free Report) had its target price lifted by investment analysts at Barclays from $350.00 to $415.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 21.68% from the stock’s current price.
COR has been the subject of several other reports. UBS Group reduced their target price on Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, October 16th. Robert W. Baird raised their price target on Cencora from $373.00 to $375.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. Evercore restated an “outperform” rating and issued a $350.00 price objective (up from $330.00) on shares of Cencora in a research report on Thursday, August 6th. Bank of America raised their target price on shares of Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $381.00.
Get Our Latest Research Report on Cencora
Cencora Stock Down 2.1%
Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping the consensus estimate of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. During the same quarter in the prior year, the firm posted $3.84 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. Equities research analysts expect that Cencora will post 19.58 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.38% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Cencora
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Cencora in the 2nd quarter worth approximately $5,154,136,000. Boston Partners boosted its stake in Cencora by 7.8% in the third quarter. Boston Partners now owns 5,247,872 shares of the company’s stock worth $1,578,543,000 after buying an additional 379,090 shares in the last quarter. Bank of America Corp DE boosted its stake in Cencora by 6.9% in the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after buying an additional 267,318 shares in the last quarter. Amundi boosted its stake in Cencora by 43.5% in the second quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after buying an additional 676,066 shares in the last quarter. Finally, Carmignac Gestion grew its position in Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after acquiring an additional 646,112 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
About Cencora
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
Further Reading
- Five stocks we like better than Cencora
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
